Introduction
Peripheral blood mobilized hematopoietic progenitor cells are almost exclusively used for autologous hematopoietic cell transplants (AHCTs) due to more rapid engraftment and convenience compared with BM-derived hematopoietic progenitor cells (BMHC). 1 An attempt to collect peripheral blood hematopoietic progenitor cells (PBHC) is usually made in patients planned for an AHCT. Up to 30% of patients do not mobilize sufficient hematopoietic progenitors into the blood stream resulting in a suboptimal (o2 Â 10 6 CD34-positive cells per kg) PBHC collection, 2 preventing subsequent AHCT. Causes of poor PBHC mobilization are multi-factorial and include prior alkylating or purine analog use, marrow involvement with disease and pelvic radiation. 3 Unfortunately a second attempt to mobilize PBHC in patients failing their initial collection is frequently unsuccessful. 4 One method to circumvent an inadequate PBHC collection is to supplement the graft with BMHC. 5 The use of CSF-primed BMHC results in engraftment times similar to that of PBHC. 6, 7 However, the use of this method in patients, failing a PBHC collection first, has had limited study. 5 Moreover, long-term engraftment data are unknown. Since 1999, we have been performing G-CSF primed BM harvests in patients in whom PBHC mobilization has failed. Here, we present our experience with this approach.
Patients and methods
The Research Ethics Board of the Princess Margaret Hospital approved this single center retrospective study. We reviewed our database and the medical records of patients with AML, Hodgkin's lymphoma (HL) or nonHodgkin's lymphoma (NHL) planned for AHCT from 1999 to 2006 inclusive, where chemotherapy mobilization (CY 2-2.5 g/m 2 on day 1, ± etoposide 200 mg/m 2 on days 1-3, followed by G-CSF 10 mg/kg daily for 7-10 days) resulted in an inadequate PBHC collection, defined as o2 Â 10 6 CD34 cells per kg (Table 1) . A second PBHC collection was attempted using SCF and G-CSF in selected patients based on physician's discretion and availability of drug insurance. Fifty-two patients with o2 Â 10 6 CD34-positive cells per kg PBHC collected were identified: 17 had AML, 11 HL and 24 NHL. Twenty-three patients underwent an AHCT with BMHC alone and 29 were infused with a combination of PBHC and BMHC. Details on their sex, age, prior chemotherapy, failed mobilizing regimens and status at transplant are presented in Table 1 . These patients are referred to as the study cases.
BM harvest procedures
All patients had bilateral BM aspirates and biopsies performed within 2 weeks of the planned harvest to exclude disease in the marrow. Patients were treated with subcutaneous G-CSF 10 mg/kg/day for 4 days prior to harvest. Bone marrow was aspirated from both iliac crests into 20 ml syringes flushed with preservative-free heparin, until a minimum of 1.5 l of BM was obtained. The harvested cells were depleted of red cells and cryopreserved; samples were also sent for culture and in vitro assays. On day 14 colonyforming unit (CFU) cell assays were performed as previously described. 8 Generally, a minimum of 3 Â 10 4 CFU-granulocyte macrophage (GM)/kg was required to proceed to harvest in patients who had no PBHC collected. This threshold was established based on our previous experience of a high percentage of delayed engraftment (time to ANC40.5 Â 10 9 /l of more than 30 days and time to plt 420 Â 10 9 /l of more than 60 days) in patients transfused with fewer than 3 Â 10 4 CFU-GM/kg in the 1990s when AHCT was performed using autologous BM only. 8 Intensive therapy All patients were treated as inpatients and received melphalan 180 mg/m 2 day À4 and etoposide 60 mg/kg day À3, with BMHC with or without PBHCs infused on day 0. Patients with AML also received total body irradiation, 12 Gy in six fractions starting day À2. All patients received prophylactic ciprofloxacin and acyclovir along with G-CSF (5 mg/kg), which was commenced 7 days after hematopoietic cell infusion, until ANC reached 1.5 Â 10 9 /l. Empiric broadspectrum antibiotics were commenced in all patients with a fever. Platelets and RBC were transfused to maintain a plt count 410 Â 10 
Statistical analysis
Engraftment outcomes were compared for patients with AML, HL and NHL who had a successful (42 Â 10 6 CD34 cells per kg) PBHC collection and subsequently underwent a transplant during the same period. A total of 422 patients underwent an AHCT using PBHC alone; 32 with AML, 135 with HL and 255 with NHL. These patients are referred to as the control population.
Hematopoietic recovery for the cases and controls, and factors affecting hematopoietic recovery were compared using the non-parametric Wilcoxon rank sum test. Overall survival (OS) was measured from the date of AHCT to the date of death or date of last follow-up, whereas progression free survival (PFS) was measured from AHCT to the date of progression or last follow-up. Treatment related mortality was defined as death within 12 months of AHCT not due to disease relapse, accidental or a second cancer. The log-rank test was used to compare the survival outcomes between cases and controls. Causes of death between the cases and the controls were analyzed in a competing risk model using Gray's test. All analyses were performed on the cases as a whole and according to underlying diagnosis. All P-values are two sided and P-values o ¼ 0.05 are considered statistically significant. All statistical analyses were performed using SAS Version 9.1 (SAS Institute, Cary, NC, USA).
Results
Fifty-two patients underwent AHCT with BMHC alone (n ¼ 23) or in combination with PBHC (n ¼ 29). Nine 
Engraftment
The median number of days to reach an ANC 0.5 Â 10 9 /l and plt count 420 Â 10 9 /l for the cases was 14 and 27 days, respectively ( Table 2 ). This was significantly longer than for the control population (ANC40.5 Â 10 9 /l-11 days, plts 420 Â 10 9 /l-11 days, Po0.0001 for both comparisons), and remained significant when analyzed by underlying diagnosis. Patients receiving both BMHC and PBHC had faster engraftment compared with patients receiving BMHC alone: median time to neutrophil and plt engraftment for BMHC-PBHC graft were 12 and 17 days, respectively vs 21 and 37 days for BMHC alone (Po0.0001 and P ¼ 0.0002). Of the 29 patients who received a BMHC-PBHC graft, 25 (86%) received three or fewer lines of chemotherapy and 13 of 23 (56%) patients receiving only BMHC had three or fewer lines of chemotherapy. The subgroup of patients who received three or fewer lines of chemotherapy (n ¼ 38) was analyzed and engraftment was still significantly faster for those receiving BMHC-PBHC, with median time for neutrophil and plt engraftment of 12 and 16 days vs 18 and 39 days for the group receiving BMHC alone (P ¼ 0.002).
For patients receiving a BMHC alone graft, we examined the relationship between the numbers of CFU-GMs infused with engraftment times. A slight reverse correlation was noted; the correlation coefficient for ANC and plt engraftment was À0.29 and À0.19, respectively, but statistical significance was not reached (P ¼ 0.18 and 0.41).
Long-term engraftment. We reviewed long-term engraftment of the cases using Hb, plt and neutrophil counts at 6 and 12 months after AHCT (Table 3) in patients who were in remission at these time points. At 6 months, nine patients had died (six from progressive disease and three from TRM-discussed below), four patients had relapsed and five did not have a 6-month blood count available. Of the 34 remaining evaluable patients, four (11%) had a Hb count o90 g/l, four (11%) had a plt count o20 Â 10 9 /l and 0 (0%) had ANC o0.5 Â 10 9 /l. Only three patients had a normal complete blood count (Hb1 120-170 g/l, plts 150-450 Â 10 9 /l, ANC 2.0-8.0 Â 10 9 /l) at 6 months. Between 6 and 12 months after AHCT, an additional four patients had died (three progressive disease and one TRM), another four had relapsed and five did not have a 12-month blood count available. Of the 28 patients evaluable at 12 months, one had a Hb count o90 g/l, all had a plt count 420 Â 10 9 /l, whereas only one (3%) had an ANC o0.5 Â 10 9 /l. Six patients had a normal complete blood count at 12 months, three of whom also had a normal complete blood count at 6 months post-AHCT.
Survival. Median follow-up for the cases was 22.4 months and their 2-year OS/PFS was 63/57% (AML), 71/71% (HL) and 56/34% (NHL).
Treatment-related mortality (TRM).
Of the 52 cases, four (7.6%) died due to TRM. There was one early death from Table 3 Median 6 and 12 month complete blood count parameters for cases Use of stimulated BM cells in autotransplant T Seshadri et al pulmonary sepsis at 11 days after progenitor cell infusion and three late deaths. Of the late deaths, two were due to complications from delayed engraftment-one at 5 weeks after AHCT of an intracranial hemorrhage, the other at 4 months post-AHCT from alveolar hemorrhage. Both deaths occurred in the setting of chronic refractory very severe thrombocytopenia (o10 Â 10 9 /l). The third late death occurred at 8 months post-AHCT from septic shock. A recent blood count was unavailable. All three late deaths had received a BMHC only graft.
In contrast, TRM of patients who received PBHC only was 2.8% (12 of 422). Four patients died within 2 weeks of stem cell re-infusion and were either pancytopenic (n ¼ 2) or had just recently engrafted (n ¼ 2). The median time of death for the other eight patients was 3 months after AHCT (range 1.5-7 months). Three of these patients had evidence of delayed engraftment evidenced by persisting pancytopenia as AHCT and this was thought to contribute to their death. Another patient died at 1.5 months post-AHCT and no recent blood counts were available. The other four patients died of various causes (one from steatohepatitis, one from leukoencephalopathy, one from cardiac failure and one from pneumonia), and there was no evidence of delayed engraftment/graft failure in these four individuals.
There was no difference in the incidence of TRM at 12 months between the cases and the controls (P ¼ 0.08).
Discussion
The purpose of this study was to examine survival and engraftment outcomes of patients who underwent AHCT following a failed PBHC collection using stimulated BMHC. Similarities in engraftment times between G-CSF-stimulated BM grafts and PBHC infusion 6, 7, 9 suggested this approach may be more effective than using unstimulated BM in patients failing a PBHC collection. A prospective trial, published by Lemoli et al. 5 , examined the utility of a G-CSF-stimulated BM harvest in patients who were poor PBHC mobilizers (defined as fewer than 10/ml circulating CD34 cells during mobilization or less than 1 Â 10 6 /kg CD34 cells collected). The majority of patients analyzed (78 of 86) were infused with BMHC alone. Patients with lymphoma/myeloma took a median of 13 and 15 days for neutrophil and plt engraftment, whereas those with AML took longer at 23 and 52 days, respectively.
Our retrospective study has several important differences to the study by Lemoli et al. 5 First, our cohort failed PBHC collection based on insufficient hematopoietic cells collected rather than on circulating CD34 cell counts (C-CD34) alone. Although C-CD34 counts correlate with PBHC yield, 10 it is still only a surrogate marker for the actual PBHC collected-the important clinical end point. Second, we examined outcomes between BMHC only grafts vs combination BMHC-PBHC grafts to help ascertain the clinical usefulness of infusing small numbers of PBHC. Finally, we reported on longer term engraftment.
The median and range for neutrophil engraftment times in our study were comparable with those published by Lemoli et al. 5 However, it appears that plt engraftment times for patients with NHL and HL were longer. Although severe marrow failure at 6 and 12 months was uncommon in our study group, very few patients actually had a normal complete blood count at these time points and considerable range, especially in the plt count was evident. Furthermore, these figures omit deaths due to graft failure and thus are not entirely representative. It is generally accepted that PBHC engraft more rapidly than unstimulated BMHC and that de novo-stimulated BMHC appear to have similar engraftment times to PBHC 6, 7, 9 suggesting that it is prior CSF exposure, not the anatomic site, which influences engraftment. 9 Accordingly, the most interesting finding in our study was that significantly faster engraftment times were seen in patients receiving combination PBHC-BMHC compared with BMHC alone-an outcome independent of G-CSF as all patients received G-CSF prior to BM harvesting.
The gene expression profiles of PBHC are different from those of unstimulated BMHC.
11 Peripheral blood hematopoietic cells tend to have lower CXCR, ckit and VLA-4 expressions 12 that influences their ability to detach from the BM stroma and mobilize into the blood stream. The exact cellular mechanisms that enable PBHC to engraft faster than unstimulated BMHC are poorly understood, but may, in part, relate to the relative increase in committed progenitors seen with PBHC over unstimulated BMHC and various other qualitative differences. 11 Whether these differences persist in stimulated BMHC obtained after a failed PBHC collection is unknown.
Treatment-related mortality was not significantly higher in patients receiving BM-derived progenitors over PBHC alone. However, given the small numbers and that two (possibly three) of the four deaths appeared to be as a result of delayed/failed engraftment, this should be interpreted cautiously.
Failure of PBHC collection will continue to be a problem for a proportion of patients. Novel agents such as the CXCR4 receptor antagonist plerixafor (Mozobil) 13 used to improve mobilization show promise. A recently published study in patients failing an initial PBHC collection demonstrated the ability to collect adequate PBHC in over two-thirds of lymphoma/myeloma patients using a combination of plerixafor with cytokines.
14 Although further study is required, these results suggest that using plerixafor may obviate the need to perform a BM harvest in the traditional 'poor mobilizer'.
We have shown that using stimulated BMHC harvested from patients failing a PBHC collection can be employed successfully in AHCT, but this results in significantly longer engraftment times compared with PBHC alone. We conclude that any PBHC that are collected should be reinfused with the BMHC, as short-term engraftment is superior to using G-CSF stimulated BMHC alone.
